Survey Form

A. Sociodemographic Characteristics

1. What is your age?
   a. 18-25 years
   b. 26-35 years
   c. 36-44 years
   d. 45 years and above

2. What is your gender?
   a. Female
   b. Male

3. What is your specialization?
   ............

4. What is your professional experience?
   a. 4 years and less
   b. 5-9 years
   c. 10-14 years
   d. 15 years and above

5. City you are working in.......... 

B. Knowledge of Pharmacovigilance

1. What is the best definition of pharmacovigilance (FV)?
   a. It is the science that determines the type and incidence of ADRs (Adverse Drug
      Reactions) after the drug is marketed.
   b. It is the science that monitors ADRs that occur in a hospital.
   c. It is the process of improving the safety of the drug.
   d. It is the science that monitors activities related to the detection, evaluation,
      understanding and prevention of ADRs.
   e. I don't know/ I have no idea.

2. What is the most important purpose of pharmacovigilance?
   a. Determining drug safety
   b. Determining the incidence of ADRs
   c. Identifying facilitating factors for ADRs
   d. Identify previously unrecognized ADRs
   e. I don't know.

3. Are you aware of the Turkish Pharmacovigilance Center (TUFAM)?
   a. Yes
   b. No

4. Who is responsible for monitoring ADRs in Turkey?
   a. Turkish pharmacological society
   b. TITCK
   c. TUFAM
   d. Turkish Medical Association
   e. I don't know
5. Are you aware of the Pharmacovigilance contact point in your hospital?
   a. Yes
   b. No
   c. I don't know/ I have no idea

6. Do you think ADR notifications are necessary?
   a. Yes
   b. No
   c. Possibly

7. According to the regulation published in Turkey on Pharmacovigilance, who are the healthcare professionals responsible for reporting ADRs in a healthcare institution?
   a. Doctor
   b. Nurse
   c. Pharmacist
   d. Dentist
   e. Midwife
   f. I don't know

8. Which of the following is/are a serious ADR? (More than one option can be ticked)
   a. Death and/or life-threatening
   b. Prolongation of hospitalization/hospitalization time
   c. Causing significant or permanent disability/incapacity
   d. Congenital anomaly
   e. I don't know

9. Within how many days should an ADR be reported to the relevant institution?
   a. 1 day
   b. 7 day
   c. 15 day
   d. 28 day
   e. I don't know

10. In the reporting of suspected adverse reaction cases; what are the minimum data that should be reported about a case?
    a. An identifiable reporter, An identifiable patient, an adverse reaction, a suspected drug
    b. An identifiable patient, an adverse reaction, a suspected drug
    c. An identifiable reporter, an adverse reaction, a suspected drug
    d. I don't know

C. Attitudes Regarding Pharmacovigilance
1. Do you consider is it a professional obligation for you to report ADRs?
   a. Yes
   b. No
   c. Possibly
   d. I don't know

2. What should be done when ADRs are suspected? (More than one option can be ticked)
   a. Medication should be discontinued and/or treated with alternative
b. The drug should be discontinued and/or the dose should be reduced.
c. Causality must be determined
d. ADRs should be reported

3. Do you think that pharmacovigilance training should be given in detail to healthcare professionals?
   a. Yes
   b. No
   c. Possibly
   d. I don’t know

4. Which of the following factors would discourage you from reporting an ADR?
   a. Insufficient time to report ADR
   b. The notion that a single unreported ADR will not affect the database
   c. Difficulty in deciding whether ADRs have occurred
   d. The absence of any reward for reporting
   e. Believing that licensed drugs are safe
   f. Consideration that the ADR is not significant enough to be reported
   g. Not knowing how to make a notification

D. Practices Related to Pharmacovigilance

1. Have you ever seen an ADR?
   a. Yes
   b. No
   c. Possibly
   d. I don’t know/ I have no idea

2. Have you ever seen the adverse effect reporting form?
   a. Yes
   b. No
   c. Possibly
   d. I don’t know/ I have no idea

3. How many 'Adverse Effects Reporting Forms' have you filled so far?
   a. None
   b. 1-2
   c. 3 and above

4. Have you ever received training on how to fill out the ADR?
   a. Yes
   b. No
   c. I can't remember

5. Is there a resource where you can get support in completing the Adverse Drug Reaction form?
   a. Yes
   b. No
   c. I don’t know/ I have no idea

6. Are you informed about the process of reporting ADRs by your institution or hospital Pharmacovigilance contact point?
   a. Yes
b. No  
c. Just education  
d. I don’t know

7. Do you follow the current developments in pharmacovigilance?  
a. Always  
b. Seldom  
c. Rare  
d. Never